Diagnosis and a Suitcase: Why Kazakhstanis with Cancer Still Seek Treatment Abroad
Fundraising appeals for cancer treatment abroad have become a familiar feature of Kazakhstan’s social media landscape. A photograph, a medical report, a bank account number and a plea for help often signal a family’s decision that treatment outside the country offers the best chance of survival. Whether that perception is justified remains one of the most sensitive questions facing Kazakhstan’s healthcare system. According to the Ministry of Health, the incidence of malignant neoplasms in urban areas reached approximately 239 cases per 100,000 people in 2024, up from 230 a year earlier. Kazakhstan records one of the highest cancer incidence rates in Central Asia, ahead of Kyrgyzstan, Uzbekistan, Turkmenistan and Tajikistan, according to recent regional comparisons. More than 30,000 new cancer cases are diagnosed in Kazakhstan each year, while thousands of people die annually from malignant tumors. Breast cancer is the most commonly diagnosed form of the disease, followed by colorectal and lung cancers. Lung cancer remains one of the leading causes of cancer-related mortality. The burden of disease is not evenly distributed. The highest incidence rates are recorded in industrial regions such as Pavlodar, Karaganda, Kostanay, North Kazakhstan and East Kazakhstan. Specialists attribute the trend to a combination of environmental pollution, unhealthy lifestyles, population aging and, according to some experts, the long-term effects of the COVID-19 pandemic. Kazakhstan’s leading oncologists generally reject the notion that treatment abroad is automatically better. The country’s major oncology centers offer surgery, chemotherapy and radiation therapy using treatment protocols that largely correspond to international standards. Physicians at the National Research Oncology Center in Astana note that many patients who travel to Turkey or South Korea eventually receive treatment recommendations similar to those available in Kazakhstan, often at a much higher personal cost. The difference, doctors and patients say, often lies in speed and service. Private clinics abroad can offer faster access to consultations, diagnostics and treatment, while patients frequently cite more personalized care and greater attention from medical staff. For families confronting a life-threatening diagnosis, such factors can become decisive. At the same time, some limitations within Kazakhstan’s healthcare system are difficult to ignore. The country’s bone marrow donor registry remains relatively small. In leukemia cases where no compatible donor can be found among relatives, patients often depend on international registries and may require treatment abroad. Organ transplantation from deceased donors also remains underdeveloped. In some cases of liver cancer, patients must travel to countries such as Belarus when no living donor is available. Some of the latest targeted therapies and immunotherapy drugs are also not yet registered in Kazakhstan, although oncologists say new treatments are gradually being incorporated into clinical practice. One of the most common complaints among patients with cancer in Kazakhstan concerns delays in diagnostics and treatment. Kazakhstan’s healthcare system formally guarantees a so-called “green corridor” for oncology patients, under which no more than 30 days should pass between the initial suspicion of cancer and the start of treatment. In practice, however, access to high-tech diagnostic equipment remains uneven. PET/CT scanners, a...
